πŸ‡ΊπŸ‡Έ FDA
Patent

US 8846908

Tricyclic carbamate JAK inhibitors

granted A61KA61K31/423A61K31/506

Quick answer

US patent 8846908 (Tricyclic carbamate JAK inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Sep 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/423, A61K31/506, A61K31/538, A61K31/5383